ZGNX - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Zogenix Second Quarter 2020 Earnings Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Brian Ritchie, LifeSci Advisors. Please go ahead.

Brian Ritchie

Thank you, operator, and thank you all for joining us this afternoon. call Executive today's Dr. on me are Officer, Chief With and Officer, Officer, Dr. Stephen Commercial Sagrolikar; Chief as Farr; Chief well Ashish Financial as Michael Smith; Quan, Zogenix Therapeutics of Medical Joanne and Chief Officer company. Modis news release afternoon, announcing results XXXX. the for issued XX, This quarter June providing financial ended Zogenix second business update a and a harbor discussed Private the Securities Reform Act. certain Please call is of note information that covered provision today the on under the safe Litigation making that listeners Zogenix' this forward-looking statements. during be caution We management call, will from those statements materially or implied and Actual associated forward-looking differ results company's stated by these due uncertainties could risks to business. with the These forward-looking in statements the in the XX-K annual are today SEC release company's Form cautionary filings. the statements Zogenix' and qualified subsequent issued contained report by included filings on press and also only contains is this that of date call as the broadcast, information August XXXX. accurate live time-sensitive conference X, of This to any or conference Zogenix or circumstances undertakes the statements events call. date after revise no of this to reflect obligation update forward-looking

Steve. call Now, I'd like to the to over Go Steve. turn ahead,

Stephen Farr

you, rare quarter last has tremendous FDA investigators, developing first of the drug I July to approval company. enabled Brian, great U.S. enrolled launch week and us program in into had excited shipped is Dravet REMS first approval good would and all product FINTEPLA done for This families ended has This We commercial a The treatment like as that as help the news at our to to with enter again, Once dedication clinical colleagues we're patients a focus Zogenix. work everyone. received strategy therapies thank of for FINTEPLA previous since integrated and commercial this biopharmaceutical achieve that on they we of our the syndrome. to program. who fully third quarter for been to seizures XX, official diseases the occurred associated us a participated the our and in tremendous commercializing our of with Thank patients, to have pivoted milestone. approval on afternoon and transformative result all my and

provide concludes an And commercial quarter. will financials Mike to I'll development before with early progress and Ashish launch the discuss our on our come programs for activities. update ongoing back our

Ashish Sagrolikar

Thank initial on excited FINTEPLA then, is in launch to Since share FDA to I'm you, on June the going the XX. approval Steve. see U.S., progress well our the following we've of extremely continued which to syndrome. both the a very community high and from level for in in patients with more provide Dravet reflecting has control need enthusiasm of physicians caregivers the this FINTEPLA for seizure FINTEPLA that and potential

the REMS program, first now new step being fintepla.com healthcare to FINTEPLA the unprecedented providers than their under in healthcare FINTEPLA ensure notable safety went education us was it in for FINTEPLA certified mentioned we that open-label happy community I’m the continue certification product prescribers to compelling of providers teamwork in current patients in an U.S., weeks early prescribers prescribe from efficacy and some was product. of patients and FinteplaREMS.com, the Dravet of within within reinforces webinar FINTEPLA. researches caregivers healthcare to are certified studies to patient This launch as XXX named the recently us to have as by community the sites access exceeded help well ongoing supply United time to which interest commercial extension the given becoming global and during have and of about especially and is prescribing initial in have conducted primary used support COVID-XX process this our FINTEPLA live distribution Zogenix team our product the of pharmacy about transition FINTEPLA, the Zogenix-centered level and information pharmacy. following our more physicians was to that caregivers provided of product commercial to patients educating to guide than to expectations, and With REMS program expanded previously, important media The to program. approval. who This on environment rollout entire objective hub and interest high pandemic. website, FINTEPLA on Through patients are all XX social collaboration for our the enrolled U.S. about now. engagement the especially FINTEPLA. FINTEPLA date Syndrome providers currently that who to Foundation, States taking this also by the in well care with report for end, is our successfully of the more July. profile specialty just attended Dravet This the Europe, have will hub the details medical finished chain community. prepared. heard and and establish distribution high few and to As strong access these the the our comprehensive the the quality delivered outstanding webinar approval, we This the members program expanded of in for We Dravet It specialty are led activities. refine to processes enabled from and prior Dravet substantial our

still Zogenix also field team educating enrollment facilitate now profile physicians safety And mentioned, with the in program. are resources sales Steve are they on launch This on FINTEPLA. the efficacy July office CP and week They our will XX, the based REMS medical of of on in educating the last and staff FINTEPLA. Central. affairs the As available

program providers contacted first our study few extension the in successfully have access open-label managers are following within patients who FDA approval. weeks expanded and account the all keeping currently healthcare key Our

number to of the of to United We FDA benefits key potential approval. allowed and are Dravet availability to discussions coverage us be promotional offer us with FINTEPLA could educate that States. we approval, advance the approximately about substantial the our focus Prior also administrators. physicians the syndrome who of continuing to with meet label now had XX% The and private for to treated payers has opportunity of XXX approved discussion FINTEPLA safety patients our only the the in them care decisions after to Medicaid payers coverage information and the

to an exciting effort to therapy have can have their will potentially coverage very of in for bring very coverage seizures families thank coverage. to that already devastating typically their we patients reduce receiving become experience. time FINTEPLA number are the U.S. we recognizing in to and transformative I want this a are support these healthcare to assist Dravet important to off to certified who already ongoing option thank providers during happy becomes Dravet community receiving this individual Reiterating continue take just launch patients also Central would positive that of what we few said, a weeks an during and this congratulate the FINTEPLA expedite pandemic. are some launch We Steve FDA In have like summary, Zogenix ongoing the the to tirelessly to proud start, to prescribers. and teams COVID-XX report determinations within started cases determinations several entire initial approval I Zogenix worked our the period. who

back Now the Steve. Steve? to I’ll call turn

Stephen Farr

anticipate In to great U.S. the of work activities Dravet marketing other a for of quarter our and providing the key summary. ongoing. CHMP for continue our that XXXX. opinion year. preparing Ashish this to In recent first parallel of we’re of we public of encouraging syndrome we in by end potential described, in Based FINTEPLA progress, European first as the country, anticipation Ashish application FINTEPLA these is In EMA’s launch regions. in advanced Europe, with you, regulators Germany, for in on review opinion, Thank the

Additionally, the in to first of submission Japan, to top half have expect in Phase line a year planned support trial fourth of quarter XXXX. in X data from we our pivotal JNDA the this

would seizures on most LGS sNDA seek our to epilepsy. FINTEPLA causes, for support Now with FINTEPLA difficult or A nonclinical I'd to September, Lennox-Gastaut specific FDA LGS. rare with correlated of feedback LGS Dravet to our we Unlike making agency's NDA the in in has is childhood LGS. which strongly the in requirements severe arise been program another different multiple the like to syndrome, syndrome to clinical supplemental variations or onset effectively among gene, during scheduled planned LGS turn a and treat. form can from and associated is which for meeting for

we communicated, population patient completed conducting successfully a X trials currently Phase and we’re and previously trial pivotal the have As X two-year safety on efficacy enrollments. pharmacokinetic Phase study convulsive

are Assuming required, LGS of studies anticipate data FINTEPLA from these during for XXXX. sNDA second a the in we quarter submitting

sNDA the trial determined on LGS approval in Dravet reminder, has an required As Phase X only one from – sNDA. positive for based syndrome, that is a FINTEPLA

MTXXXX. to like to I'd Now switch

functions characterize this deficits MTXXXX restore PRIME oral an United disorder deoxythymidine as mitochondrial the treat devastating that as for MTXXXX and X fixed-dose and therapy investigational deoxycytidine in in mitochondrial therapy a of fatal regions. feeding Europe, well in deficiency, or therapy treatment designation called disease. has as States designation enhancement the treatment DNA depletion frequently respiratory that breakthrough designation devastating to orphan kinase is TKXd. Our in and DNA combination serves both substrate progressive and motor, thymidine of and

planned quarter, During submission we’ll MTXXXX. discuss to for the development the to support path second for NDA the twice the FDA

outcome historical the the a the patients basis survival as for from control with that to which is an pleased of very group are our benefit external discussions, proposal We compared treated these reasonable supports NDA.

in a previously patients of patients study retrospective compared the we've an TKXd, the XX a of TKX significant deficiency which XXX, from As nucleosides with to statistically literature. treatment control a effect reminder, of completed to demonstrated pyrimidine entry Study survival on of group combination

additional in with open-label prospective patients, who survival in our been Study treatments complete Unfortunately, did have intend FDA the NDA from sites for include to continued a are XXX. that of Study Study U.S. any our to to in analysis, has restricted to Europe this patients XXX for addition XXX NDA. the by clinical study participated analysis COVID-XX. part that responsive particularly some information to in addition Study no patients we those traveling complete not treated to At order Study and XXX Note MTXXXX completed in we on as impacted the obtain provides ongoing outside In assessments. participate submission. from who requested XXX, study a

hepatic However, respect requested from in from the dosing studies patients have regulatory feedback renal uninterrupted With to this the impairment been Phase MTXXXX to a recommendations continue the function. impaired treatment other setting to I provide conduct renal pandemic. during with that we meetings, able of FDA

in duration the The FDA months, study NDA non-clinical accept three duration the would submission. of study but toxicology we dogs, versus a recently toxicology a completed nine typical a have we months a that concerns requested of the to in longer was delay willing Regarding months rats. toxicology, should minimum six substantially also study study

CMC the submission. all In related accepted future addition, the FDA for our plans

an his for the to data certain of by to submission will let me anticipate XXXX, NDA to relaxation With Assuming restrictions all in in COVID-XX, of related XXXX. financial call support of Mike half over first for hand order end Mike? be we review. the available that that, the the

Michael Smith

the of by Thanks, million Today, increase in second Steve, quarter FINTEPLA $XX.X ended press in expenses of financial for to Shinyaku Study June [indiscernible] III is R&D in million XX, release syndrome everyone. the the personnel in attributable million a increase our spending This XXXX. the our our in to distribution related our results the XXXX. $X XXXX. and Phase We Dravet result decreasing I’ll operational spending LGS program. for we issued an $X is the and modest during $XX.X MTXXXX second costs exclusive were in This through. XXXX, clinical for of We late series recognized in our million, million quarter expenses run in in which of an and good business a now LGS all development candidate for in afternoon, period Nippon from announcing in first revenue recognized quarter revenue $X.X Dravet Japan. with offset correspondence study, partially corresponding increase approximately XXXX increase syndrome stage collaboration

share we million payment quarter end at tax and $XX.X to loss for XXXX number Europe $X.XX for contributed which related of per ended XXXX. our the quarter highlight the net And in primarily prospectively significant securities to the from the operator additional continued share. and open to robust sheet the and and TKXd. loss in medium the key relief to the ended million was cash totaled and have quarter by start quarter, the second launch to Dravet to Q&A $XX.X quarter $XX.X or first the current in of government This advanced XX, the million the call and with now qualify of scheme. Operator, per began the in successful ended compared XX, in One allows for the June of We I’ll total or to item approximately prior the in beginning you line development preparations quarter ended simultaneously XX, stage SG&A expenses $XX.X FINTEPLA of increase please in come position cash important our R&D us tax session. closure. the $XX.X strong launching of in June payment for launch quarter to $X to U.S. to the studies related second questions? balance. in $XXX for the credit received our LDS, this year. R&D prevalent $XX our with June With a syndrome MTXXXX in and area or related treatment FINTEPLA in that, U.S., balance million, the activity million Dravet for UK a FINTEPLA XXXX XXXX enterprises that of marketable for size second million can that small invest the a of $X.XX programs under and late FINTEPLA quarter driven XXXX. the turn UK syndrome with The over of cash Net second As in with investment in that’s XXXX compares Europe, the

Operator

Instructions] comes Stifel. Thank take you. our And first Paul it [Operator Matteis from question, from we’ll

Unidentified Analyst

real on question. quick. first launch else? on for something taking providing patient you the Thanks Maybe Hey for are metrics one guys, planning this What starts or guys Nate is Paul.

Stephen Farr

Ashish, to mute. are on you you that like take Ashish question?

Ashish Sagrolikar

I’m sorry. Paul, thanks for the question.

be that as will today, launched with And experience week. a metrics well various with said clinicians just the that as can trends evaluating we source to and certification one measures completing in We appropriate reflect key our we from the provide patients, the launch. the of upcoming payers reliable as we last the will that the and is which of provide is the what communication, program shared. enrollment expect in physician we REMS metrics, And of progress more information

Unidentified Analyst

you patients drug? kilogram the Got they’re of What’s the quickly dose the you. And you on U.S. or think they’re about transition how from the to think to LGS. going per I XXX do in And Dravet then average basis? XXX said commercial to on, over a

Ashish Sagrolikar

patients. that extension get think early I access you’re and referring open-label to Yes, the I the program Did right?

Unidentified Analyst

Yes, exactly.

Ashish Sagrolikar

Yes.

on transitioning So we patients. are working these

will as to So to in done these of first have part and and physicians will we these reach last be mind patients keep they need enrolling echo most to that have in able their baseline. to is plan that the not And thing say together. all in OLEs the programs echo the been start in now the to the be EAP of I’m almost they proud have therapy,

going to be So they trial. here we The need for to takeaway not interruption, – will to do And popped most will is then result. that through this allow the transition We the they then is clinical strong we a being continue hence important be far closure working and coverage. into for determination patients as a are on the in program any to there as them decided. get coverage as trial have able that receiving getting process we that do is therapy, the patients

Unidentified Analyst

dose Got they you. average what are? And

Ashish Sagrolikar

was was milligram time and X.X that the average we XX.X dose was the dose last the kilogram. talked So average average date per

Unidentified Analyst

very much. Thanks it. Got

Stephen Farr

Thanks for questions. your

Operator

And from can next Goodman This SVB Marc now you. move our Thank we question. of to Leerink. comes

Roanna Ruiz

question. Marc. Thanks the on is taking Roanna two. This the have I line for Hi. for

for the clarify data asset, clinical process was what you and work you could Modis during portion? extra previously know what some prepared First, done has remarks, for FDA like MTXXXX I requiring I the the work were but your don't doing?

Stephen Farr

of Yes, And line. I'm to also Officer if anything on can And answer Quan, be happy that. also Joanne I'd Medical here. missing the add Chief Modis she there's that

Study is we be treatments not control. their the able a all Study of for extension which is survival including where XXX, which been So be those NDA are we've MTXXXX – study also for the now on an basis we've the from speed high benefit. who patients to because establish completed information from clinical taking XXX, perspective, we'll will that's And the major This to disease.

Modis in studies. I be to will who and team with addition her prepared In the of obtaining remarks that, on of as studies our Joanne said [indiscernible] other not – patients been were treated as the information our part or have

those from be order in complete for to obtaining the we'll FDA. information So survival patients analysis the

to renal FDA to addition did In study in a conduct and ask us impairment. the that,

study. phase a that's one So

the And of if you'd missed NDA. that I've to will anything me add. let also like be part know package the clinical So for Joanne, that

Joanne Quan

No, address question. that because I think that's your good,

Roanna Ruiz

helps. are other FINTEPLA quick Yes. over enrollment a from REMS And into back time. certification these how Could going July? and be or like and mostly would sites you to did switching That then talk one it centers academic one look about, bit physicians

Ashish Sagrolikar

the Yes. questions, Thanks for Roanna.

have and academy the Could And mixed. so the about and process. been I we've your XXX think the that centers. almost They patients periodic certifications around reach treat community able certified far, they think get [indiscernible] them half are of answer and from who are XX% question? we the Dravet to of from I They are centers.

Roanna Ruiz

you Yes. And anecdotal about have if any comments July?

Ashish Sagrolikar

have launched we and thing we’ll I just and of And we got also response would the lot last caregivers a from watching the the trend. because the conversation. with excited we no that is, time, are on say this be physicians, At two really one that payers

go we process. very able this the that the feeling therapy through to we’ll as bring patients to of really be are we the we So, most confident launch

Stephen Farr

ask on what is? question Sorry, July can your I

Roanna Ruiz

basically. just about overtime wondering cadence I was when

Stephen Farr

Got you.

what all. happens you we’ve go [indiscernible] on given through that July. number in of That’s the reflects kind So

Roanna Ruiz

you. Okay, thank

Stephen Farr

that’s see to want that. I clear.

Michael Smith

Yes.

way other really physicians say, seen The a a great we’ve movement REMS the of program. to obviously, into –

this think of should treatment Dravet syndrome. I underscore, I it and the importance of the think drug

plus really XXX involved physicians good into getting So, it’s I a the stuff for think REMS, us.

Roanna Ruiz

Thanks. good. Sounds

Michael Smith

Thank you.

Operator

Thank comes next Suneja from move you. Partners. This we’ll question. to Yatin our Guggenheim of And

Unidentified Analyst

get then for certain is take how Yatin. can sense you Eddie at will membership get a was for this is if Congrats and us to first assumption guys. and XX%, some slower Hey, speeds how for and FINTEPLA? a and about broader long launch. balance the is on the gross Florida Texas there net of expectations to that is And could long it it that to give take the will are of things reimbursement. your get like Thanks. for I just FINTEPLA what wondering the reasonable

Stephen Farr

Ashish, questions. go those ahead and take

Ashish Sagrolikar

Yes.

the of from the it launches know, the to time months it some part you emphatic as up that to taken of what take six does seen it’s have generally got So, in launch reimbursement get coverage. perspective, time, you and the recent

months. You few may And which kind Yes. private they take have Texas, happen we some reviews, P&T have we up some like states on next and own now, scheduled in and six two them and months. things we information. And payers. their then scheduled to the them the may then have have states have also providing

over think I see will So, a we the huge in coverage. months, next six the increase

very providing the guidance will I time. point So gross coverage side. the think the this, From to in be that net, this is on at premature to it

on in get will We the provide future, coverage how guidance evaluating based will but the importantly and we that on goes, we more be that. how launch

Unidentified Analyst

Thanks.

have do ratio seen the increased that the that unemployment, are number population, country Just in you one seen that of to the pandemic expect for given some change? one Medicaid you of and the last increases Medicaid

Stephen Farr

Yes.

population general, of can look say, Medicaid and yes, should population, at up if the numbers that the increase. in you we kind patient So, look

seeing, because But we eight too in and product, the In terms government paid we XX% are are products working that we we what anticipate the or anything, – from of have say to that of just other our Medicaid it’s on population it’s will up form GWS patients be insurance. seen started early or some XX% been days similar since to have like of and that to what some not expect that. of

Unidentified Analyst

Thank you so much.

Stephen Farr

Thank you.

Michael Smith

you. Thank

Operator

our to Thank you. of Yang next We can this from comes Mizuho. Difei question, move

Alex Allen

good you if Hey, on a on coverage little just is would afternoon, Difei. any terms few determinations another Can additional of comment the be on ahead, for This are just question color a bit in tracking that’s of noted Alex you just the already. that a long I insurance sort everyone. positive determinations had expectations helpful. coverage

Stephen Farr

that launch coming question, yes, this really the prior to this we the for Alex. educating tracking the have our point that and expectation, for the Thanks at point At done work – it’s we bear payers time, relationship in the is and and time. have the in to

would expectation. I the tracking So, to say it’s

Alex Allen

any some just data? disclose the months one guess point great. so? you. do you plans in have question more then follow-up any Okay, MTXXXX, or Thank And to next at few additional I

Stephen Farr

want you that we will take be do Joanne, – or one [indiscernible]. are attending to we

things So maybe you that. few can for say

Joanne Quan

aspects that several of we’ve have We program. been in presenting the terms there XXXX

the think point that I that be even share I would to next publicly. So, would share

Alex Allen

Great. Thank you.

Operator

from Serge We’ll now next this comes move you. Needham and company. our Thank of question, Belanger to

Unidentified Analyst

[indiscernible] Hi, from two Serge. This got is questions. I good afternoon. for

So, about the REMS. one first it’s

patients quarters Japanese coming second to type with any terms – quarters? program you of out X REMS there have? to Phase the and fast milestones expect numbers the me them you. are of milestone these And any in consider then of in you are to themselves disclosing physicians? question XQ into Could be read that in the is remind other trial. regulatory the the how any enroll information And payments that the and that tied is you in going you Thank do trial the doctors So, Dravet

Stephen Farr

Ashish take the maybe the Mark, take can question first the questions, two [indiscernible]? you about

Ashish Sagrolikar

REMS in enrolling patient patients they on Program. depends terms what to of in So are. type It Dravet of

is As access it believe go because clinical electronically trials, what are that events, able to directly, thing not they enroll to have the is document you be have fairly the are when going smooth have we to they enrollment these the from download can available visit find the patients can then based them. some mobile, earlier the are the on website, be on a is you And quickly. early and I should do got on they in One able through documents they available to we said, their physician, the echo. mobile program

have we made much So it easier.

For patients, time. the naïve the same it almost takes

only have the is the go echo naïve to think going there patients to be step I through process.

going the institute for. they're on four to week as the half, is earlier do that have to your the where we far last, expected. Mike? what So have assignment, said the that say will find it particular And between would depending echo to in an absolutely going we echo. ability available take two seen to big weeks, But takes on going we institute and and are so I as a had enrollments depending

Michael Smith

Yes.

a through couple our there J-NDA submission for as that listing, horizon. our are term, to approval and the of Shinyaku, a well after more comes than more on the relate the are for tied price not Dravet near amounts The near So LGS Nippon with collaboration term near payments as then term much approval. to an right NDA submission which in subsequently [indiscernible] and in Japan in

payments neighborhood the of same a come of the both amounts the of as ongoing are then we'll those combination is XX in delay in terms come combined. payments. bit which And little in LGS, high with and types will marks mid-teen in – those and out milestone time have well after it's So payments of and milestones those in

Unidentified Analyst

you. Thank it. Got

Stephen Farr

your Yes, questions. for thank you

Operator

next from to Tim And Lugo of Thank our question move now William we’ll you. Blair.

Unidentified Analyst

for Tim. is Thanks this for Hi, question. on the Sean

Just us. two from

if do And focused just the like any have you see size are Thanks. pandemic? it? getting factors anything updated study I'm on how sure of the given So you the guys before first, prepared potential us, restarting in not if patients? sites and updates second, REMS I FINTEPLA? additional haven’t it there more more is for wondering are of specific Are on regions, missed certified? local thinking focused state about you start prioritizing to you And Are other I'm the of you looking you on number efficacy you remarks,

Ashish Sagrolikar

to one and you. Stephen I’ll take the it first give

So certifying key of which prioritizing [ph] the patients. cheat who and are pediatric in approximately remarks, terms prioritization, these are of in terms from epileptologists there where XX% John of are XXX we neurologists around they – the epileptologists

the will to to initial of be we that where them launch. our And then reaching it are I So we be to the entire focus is the field going team’s note, go a you But And done one. going first. is see call next what in once to this is phase as if have or in from offices, these limitation through primarily solutions most entire through geography able of enrollment the been if we the COVID process to from have online. with because devices. connect of situation, the have Zoom person, not we because And made online, these telephone, enrolled available the easily And calls. different

then we to that hopefully with these Steve? set. the will and epileptologists next answers question key first your that So go

Stephen Farr

a you with [ph] inappropriate respect situation of difficult time. because put and at probably was new John to COVID-XX hold study, and really done know, the basket thanks. our realization Yes, on it study the initiate clinical as we the to

since had Dravet. we an on clearly on on going have an approval FINTEPLA in we eye what's So kept

we at started running. epilepsies to and one But there's see several of there have protocol to study don't see I running. and divided opportunities in patients if timelines encephalopathies can whether some to study through some of different the bringing this is severe look cohorts. to into we they We least get if back and opportunity evaluating under or now, get in recall up And assumed have or various as epileptic cohorts looking study into of of up are this an but get for just be see everyone. actively to cohorts will sort And we're the that these we any not right

some information. talk will about more we more once So certainly we got that,

Unidentified Analyst

And congrats on Great. Thanks. the launch.

Stephen Farr

you. Thank

Michael Smith

much. you Thank very

Operator

to of we question, our next Michael Ladenburg Higgins move [Operator this Instructions] comes from Now Thalmann.

Michael Higgins

have I operator. Thanks, two questions.

First of all, outline seems your characteristics. SUMAVEL, benefitted congrats from the launch of to it on amongst the

out nurses, break do just target signed healthcare mentioned Thanks. opportunities have these two include also any and that? for Can little half physicians you being across? site back far. a the of up many how You've you so XXXX? spread give And of so providers I assume us goals

Stephen Farr

Michael. you, Thank

Michael. As you that breakdown, have

Michael Smith

back At that able will we don’t of there breakdown them. are I because that confidentially to XX% have to that actual but you we nurse terms is clinical that I this of time, maybe part in sites, we've be come like, and What because the have can been signed practitioners do they is few physician can how the know on reach many you all of physicians. store were what that breakdown, assistants, of trial these the physicians, give the tell you

the patients, which terms I sure Dravet be epileptologists that all may signed target, the to move to goal, the get them epileptologists and we and then goal of is said been next is or earlier, than, up keeping In on two enrolled XXX faster target one that maybe has them our as end. we want make to reached we other their to these

definitely they can their that offer So patients. from

Michael Higgins

little just Thank you. And give us That's help this. with Okay. a helpful.

some patients for sort one on were I off you there work there's that, assume is months supplies at And that mentioned something calls, no do a normally protocol How that several patient a transition that that well handling those every is that them send bills. of do handled? that this time? during prior month they how to period. a for as You’ve – as if missed the

Stephen Farr

play understood that back question, it. so your me Let I

how we transition and is much do the supply bills from the this we handle period? how did during that question transition, right? the Did get I So regarding

Michael Higgins

Yes.

Stephen Farr

Yes.

that providing get the be during transition and a bit we are insurance based based you guidelines we will trial, determination made. that transition follow then quarantine And based on and we continue what will companies how will lead to So is that, from XX-day we the provide product to product. on the the on switch follow-up as coverage or continue a either to commercially

Michael Higgins

period? the typical What is transition

Stephen Farr

early say we week. At this started this to time last because really just it's

this better numbers? in premature metrics will be hopefully point it in have So we the could say to pretty but time, at future,

Michael Higgins

guys. Thanks, feedback. the appreciate Okay,

Stephen Farr

Thank you.

Operator

call at further Thank back time you. have hand Stephen to Dr. this And so Farr. I'll we the questions, no

Stephen Farr

promising call a today. our becoming on our use pleased a of tremendous showing launch diseases. already progress in very commercial us We're few devastating joining and updates for some all forward to with providing to efficacy pleased, very, on candidate, you in thank of stage, activity. clinical extremely and and operator, progress, Look those company, our kinds ready strong pipeline to with very therapeutics you, eights share Thank

you for all day. again a of thank and So rest us your enjoying joining call the today on

Operator

This all concludes participation. today’s your call. Thank for you

You may now disconnect.

Zogenix (ZGNX) 5 Aug 202020 Q2 Earnings call transcript